Review 2: "Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia"
An anti-interleukin-6 antibody, tocilizumab, was found to have no significant differences in mortality or clinical outcomes at day 28, but shorter median time to hospital discharge, compared with placebo in a rigorously conducted randomized control trial.
Created on
Oct 16, 2020
Published on
Oct 16, 2020
Last released on
Oct 21, 2020
Cite As
Kishimoto, T., & Kang, S. (2020). Review 2: “Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia.” Rapid Reviews Infectious Diseases. https://doi.org/10.1162/2e3983f5.bede4538
DOI
10.1162/2e3983f5.bede4538
Contributors
TK
Tadamitsu Kishimoto
Professor, Osaka University: Osaka Daigaku, iFReC, Japan